Abstract
Background COVID-19 has a highly variable clinical presentation, ranging from asymptomatic to severe respiratory symptoms and death. Diabetes seems to be one of the main comorbidities contributing to a worse COVID-19 outcome.
Objective In here we analyze the clinical characteristics and outcomes of diabetic COVID-19 patients Kuwait.
Methods In this single-center, retrospective study of 417 consecutive COVID-19 patients, we analyze and compare disease severity, outcome, associated complications, and clinical laboratory findings between diabetic and non-diabetic COVID-19 patients.
Results COVID-19 patients with diabetes had more ICU admission than non-diabetic COVID-19 patients (20.1% vs. 16.8%, p<0.001). Diabetic COVID-19 patients also recorded higher mortality in comparison to non-diabetic COVID-19 patients (16.7% vs. 12.1%, p<0.001). Diabetic COVID-19 patients had significantly higher prevalence of comorbidities, such as hypertension. Laboratory investigations also highlighted notably higher levels of C-reactive protein in diabetic COVID019 patients and lower estimated glomerular filtration rate. They also showed a higher incidence of complications. logistic regression analysis showed that every 1 mmol/L increase in fasting blood glucose in COVID-19 patients is associated with 1.52 (95% CI: 1.34 – 1.72, p<0.001) times the odds of dying from COVID-19.
Conclusion Diabetes is a major contributor to worsening outcomes in COVID-19 patients. Understanding the pathophysiology underlining these findings could provide insight into better management and improved outcome of such cases.
Highlights of the Study
A significantly higher proportion of COVID-19 patients with diabetes mellitus required admission to the ICU.
Higher fasting blood glucose was associated with higher risk of COVID-19 associated mortality.
COVID-19 patients with diabetes mellitus had significantly higher incidence of complications including sepsis, ARDS, cardiac failure and renal failure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was obtained for this study
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Standing Committee for Coordination of Health and Medical Research at the Ministry of Health in Kuwait reviewed and approved this retrospective study (Institutional Review Board 2020/1404). The Standing Committee waived the requirement for written informed consent because of the urgency of data collection and the exceptional nature of the disease. All procedures involving human participants were performed following the relevant guidelines and regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data presented in this study was made available on springer nature data depository.
